Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bilateral AAV5-hRKp.RPGR gene therapy for RPGR-associated X-linked retinitis pigmentosa
NL-OMON52296Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP) and retinitis pigmentosa (RP) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline to Week 52 in binocular vision-guided mobility assessment. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NL-OMON52296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52296.